Cellerant, U.S. Department of Health and Human Services cancer, other news
HHS's Biomedical Advanced Research and Development Authority (BARDA) exercised its second option under a 2010 contract and awarded an additional $47.5 million to Cellerant to continue development of CLT-008 for acute myelogenous leukemia (AML). The funding will be used for a Phase II trial in AML, which is slated to start this quarter, and non-clinical studies required for approval in treating acute radiation syndrome (ARS). As part of the option, BARDA also extended the contract period to December 2016 and awarded an additional $18.6 million to Cellerant, bringing the total potential value of the contract up to $188.5 million. The contract comprises an initial two-year period valued at $80 million, with three options to extend the contract period. Cellerant said BARDA exercised the first option in September 2012 for $36.4 million. The third option remaining under the contract is valued at $24.6 million (see BioCentury, Sept. 6, 2010; Sept. 19, 2011 & Sept. 10, 2012). ...